Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics.
Antithrombotic therapy for the acute management of thrombotic disorders has been stimulated and guided actively by our current understanding of platelet biology, coagulation proteases, and vascular science. A translatable platform for coagulation, based soundly on biochemistry, enzymology and cellular events on platelets and tissue factor-baring cells, introduces fundamental constructs, mechanistic clarity, and an unparalleled opportunity for accelerating the development and clinical investigation of both disease- and patient-specific therapies. In the current review, we build upon and expand substantially our observations surrounding nucleic acids as antithrombotic agents.
Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina 27715, USA. Becke021@mc.duke.edu
Richard C
RC
Becker
Thomas
T
Povsic
Mauricio G
MG
Cohen
Christopher P
CP
Rusconi
Bruce
B
Sullenger
D052157:Aptamers, Nucleotide / Q000627:therapeutic use*; D001779:Blood Coagulation Factors / Q000037:antagonists & inhibitors; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006801:Humans; D052156:SELEX Aptamer Technique
D052157:Aptamers, Nucleotide; D001779:Blood Coagulation Factors; D005343:Fibrinolytic Agents